The Fluidigm qPCR analysis yielded a panel of five genes (PROK2, ZNF238, AQP9, CYSTM1 and ANXA3) as a potential HD biomarker set, and this was validated in both the original cohort and an independent validation cohort. The gene discussed is CYSTM1; the disease is Huntington disease.